rotigotine intranasal (SPM 952) / UCB - LARVOL DELTA

Stearyl amine coated liposome of rotigotine alleviates cognitive deficit in Parkinson's disease induced mice model: modulation of oxidative stress, and motor coordination. (PubMed, Drug Dev Ind Pharm) - "The study was conducted to evaluate the brain targeted delivery of cationic liposomes of rotigotine via nasal route, addressing the limitations in brain penetration for Parkinson's disease intervention...The optimized liposome, LR12, was surface modified with stearylamine at three concentrations to confer a cationic charge...The cationic liposome RTG-LP3 demonstrated effective delivery of liposomes with superior therapeutic effects in treating PD via nasal route. These findings highlight the potential of cationic liposomes as a viable method for improving brain penetration and neuroprotection in PD therapy."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Current Status and Challenges in Rotigotine Delivery. (PubMed, Curr Pharm Des) - "Neupro® was the first marketed transdermal patch formulation having rotigo-tine. There are challenges that remain in other routes of rotigotine administration such as oral, parenteral and pulmonary whereby resolving these challenges will be beneficial to patients as they are less invasive and easy in terms of administration. This review compiles recent work on rotigotine delivery, challenges and its future perspective."

Journal

Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease. (PubMed, Int J Pharm) - "Behavioral and biochemical testing of RNPs in haloperidol-induced PD rats showed a reversal of catalepsy, akinesia and restoration of swimming ability. The results from the animal model of PD show that intranasally-administered RNPs enhanced brain targeting efficiency and drug bioavailability. Thus, RNPs for nose-to-brain delivery has significant potential to be developed as a treatment approach for PD."

Journal • Preclinical • CAT

Facile Nose-to-brain delivery of Rotigotine-loaded Polymer Micelles Thermosensitive Hydrogels: in vitro Characterization and in vivo Behavior Study. (PubMed, Int J Pharm) - "In comparison with the intravenous group, the distribution of ROT in olfactory bulb, cerebrum, cerebellum and striatum was 276.6%, 170.5%, 166.5% and 184.4%, respectively. In conclusion, the ROT-PM-TSG system has proven to be a potential application prospect as a ROT nose-to-brain delivery system."

Journal • Preclinical

Fabrication, Optimization, and Evaluation of Rotigotine-Loaded Chitosan Nanoparticles for Nose-To-Brain Delivery. (PubMed, Pharmaceutics) - "A histopathological study showed that the nanoparticulate formulation produced no toxicity or structural damage to nasal mucosa. Our results indicated that rotigotine-loaded chitosan nanoparticles provide an efficient carrier for nose-to-brain delivery."

Journal